Skip to main content
Figure 2 | BMC Neurology

Figure 2

From: Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study

Figure 2

PDSS-2 total score, PSQI global score, number of awakenings during night time, and number of nocturias, FAS, LOCF. “Before rotigotine add-on”: baseline; “after rotigotine add-on”: end of maintenance. †95% CI does not contain zero (for change from baseline [i.e., before to after rotigotine add-on]). PDSS-2: Parkinson’s Disease Sleep Scale; PSQI: Pittsburgh Sleep Quality Index; FAS: full analysis set; LOCF: last observation carried forward.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us